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Abstract
Genitourinary Syndrome of Menopause (GSM) is a chronic and progressive condition
that affects a significant number of menopausal women. This recently coined term encompasses
a myriad of urogenital symptoms that are directly associated with the loss of estrogen. Women
who are afflicted by GSM can experience genitourinary discomfort, pain, and incontinence and
may be at higher risk for considerable clinical complications. As a result, GSM can impact a
woman’s physical, emotional, social, and financial well-being. Additionally, GSM can lead to
increased medical costs and elevated resource utilization and healthcare burden. Despite the farreaching impact of this syndrome, however, it remains largely underdiagnosed and undertreated.
The reasons for this treatment gap are multifactorial and include social stigma related to
menopause, lack of awareness of relationship between hypoestrogenic state and symptoms,
limited provider education on GSM and its management, and generally unwarranted safety
concerns regarding treatment options. Genitourinary Syndrome of Menopause causes
considerable and far-reaching harm and needs to be more effectively managed at all healthcare
levels.
To help reduce the GSM treatment gap among primary care providers in a large South
Florida healthcare system, a quality improvement (QI) project was designed to enhance their
awareness, knowledge, and screening of this condition. An evidence-based educational video
presentation was created and utilized to inform clinicians about GSM’s impact and the different
treatment modalities that are currently available for its stepwise, judicious management.
Additionally, a screening tool was introduced during the presentation to help facilitate
identification of GSM. Pretest and posttest surveys helped quantify the change in clinicians’
awareness, knowledge, and screening of GSM. The scores of these surveys were statistically
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analyzed and compared. The results pointed to a significant increase in knowledge and screening
following the intervention. The small size of this study may limit its relevance, but points to the
value of provider education in GSM management and, in turn, the enhancement of
postmenopausal women’s health.
Keywords: genitourinary syndrome of menopause, postmenopausal, video-based provider
education.
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Chapter I.
Introduction/Problem Statement/Significance
Background
The end of the childbearing years often brings significant changes in a woman’s life.
During this time, women are often experiencing multiple social and psychological challenges,
including shifting family dynamics, aging parents, changes in earning capacity, and financial
stressors (Wiemers & Bianchi, 2015). In addition, many of these women are entering menopause
and are undergoing hormonal changes that can significantly alter their health and well-being
(Hildreth et al., 2018). For most women, menopause is a natural biological process that signals
the end of a woman’s reproductive capacity and typically occurs between the ages 45 and 55
(Santen et al., 2014). Although menopause usually represents a natural transition, it is by no
means an easy process for many women. According to Manson and Kaunitz, a significant
majority of women experience symptoms ranging from mild to severe, and which encompass
physical, emotional, and even cognitive alterations with the potential to considerably impact
quality of life (Manson & Kaunitz, 2016). In particular, women can suffer from significant
genitourinary symptoms associated with the loss of estrogen, and which can include vaginal
dryness, dyspareunia, post-coital bleeding, vaginal burning and itching, urgency, frequency,
urinary leakage, incontinence, hematuria, and recurrent urinary tract infections (Biehl et al.,
2019) This constellation of symptoms is formally known as genitourinary syndrome of
menopause (GSM) and can afflict as much as half of all menopausal women (Mastroianni et al.,
2020). It is this syndrome that is the main focus on this research study.
Genitourinary syndrome of menopause is a relatively new name used to describe various
vaginal and urinary symptoms experienced by women of menopausal age. Previously referred to
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as atrophic vaginitis or vulvovaginal atrophy, the name was changed in 2014 when the
International Society for the Study of Women’s Sexual Health as well as the North American
Menopause Society proposed that this new term could better reflect the myriad of symptoms
experienced, and which not only included genital concerns, but also encompassed urinary tract
disorders and associated sexual impairments (Portman & Gass, 2014). GSM is directly
associated with the decreased levels of estrogen experienced in menopause and which cause
pathophysiological changes to the labia majora and minora, clitoris, vagina, urethra and bladder
(Bachmann et al., 2020). This hypoestrogenic state leads to symptoms that include vaginal and
pelvic pain or pressure, vaginal dryness, irritation and/or vaginal burning sensation, itchiness,
decreased elasticity, vaginal swelling and tenderness, increased vaginal friability, urinary
frequency and urgency, urinary leakage and incontinence, painful urination, hematuria, and
recurrent urinary tract infections (Gandhi et al., 2016). As a result, GSM can cause significant
clinical complications, which include vaginal atrophy, reduced vaginal secretions, pelvic organ
prolapse, vaginal vault prolapse, vaginal and introital stenosis, cystocele and rectocele, and
urethral atrophy and prolapse (Gandhi et al., 2016). These broad and pervasive symptoms can
lead to medical complications, sexual disturbances, relationship problems and dramatically alter
a woman’s physical, emotional, and psychological health and sense of well-being at a
particularly challenging juncture in her life (Mastroianni et al., 2020).
Currently, there are very effective therapies for the treatment of genitourinary syndrome
of menopause. Non-hormonal, over-the-counter treatments include vaginal lubricants (Replans,
K-Y Liquid) and are readily available, while prescription options include prasterone and
ospemifene, which are marketed for the treatment of menopause-related dyspareunia (Rahn et
al., 2014). The most effective treatments for GSM, however, are vaginal estrogen formulations
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(Biehl et al., 2019). These treatments are clinically proven to reduce the troublesome effects and
complications of GSM and maintain a high safety profile, even among those women for whom
systemic hormone therapies might be contraindicated (Biehl et al., 2019). These treatments are
so effective, that The North American Menopause Society recently issued a position statement
supporting the use vaginal estrogen therapies for women who do not respond to non-hormonal
treatments (North American Menopause Society [NAMS], 2020).
Problem Statement
Despite the severity of these menopausal symptoms and the availability of effective
therapies for GSM, however, most women go untreated. It is estimated that only 20-25% of
women afflicted by this condition seek treatment (Qi et al., 2020). The reasons cited by women
for this inaction often include social stigma and embarrassment associated with menopause, lack
of awareness of menopause as the cause of their symptoms, and lack of education about
treatment options (Kingsberg et al., 2019). Most concerning is the knowledge gap that exists
among clinicians when it comes to treatment of menopause. Studies show that clinicians often
lack thorough education on the management of menopause symptoms and, as a result, many lack
awareness of the relationship between hypoestrogenic states and genitourinary symptoms or may
feel hesitant to prescribe medications due to generally unwarranted safety concerns (Mastroianni
et al., 2020). This knowledge gap may be further compounded by the provider’s own discomfort
in broaching the often stigmatized subject of menopause (Mastroianni et al., 2020). The end
result is that women who are experiencing GSM often suffer in silence. The quality improvement
project presented in this paper aimed to improve primary care provider’s awareness, knowledge,
and screening of GSM in an effort to decrease the existing treatment gap and improve the lives
of afflicted women.
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Significance
It is estimated that there are approximately 50 million menopausal women in the United
States, with about half or more of these women experiencing bothersome genitourinary
symptoms (Manson & Kaunitz, 2016). This means that approximately 25 million women are
suffering from GSM at any given time, with only a small percentage receiving treatment for their
symptoms. The consequences of this lack of treatment can be significant. From a financial
perspective, women with untreated GSM symptoms experience loss of productivity,
absenteeism, increased medical complications, and increased potential for surgical interventions,
to name a few (Assaf et al., 2017). Most importantly, women who do not receive treatment must
cope with significant physical, psychological, and emotional burdens, as GSM not only affects
their bodies in consequential ways, but also impacts their sexual health, interpersonal
relationships, social activities and general sense of health and engagement with the world
(Mastroianni et al., 2020).
According to a recent position statement by the North American Menopause Society, the
hesitancy by both patients and providers to address menopause and the subsequent
underdiagnosis and undertreatment of GSM can be improved by increasing provider awareness
of this syndrome and its current treatment recommendations, and by opening the lines of
communication through the implementation of routine GSM screening among perimenopausal
and postmenopausal women (2020). Utilizing these recommendations as a springboard for
action, a quality improvement project was proposed and designed to address GSM management
in primary care, the principal point of care for most afflicted women.
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Chapter II.
Literature Summary and Related Evidence
Literature Search
The literature search for this study focused on three distinct research areas: Treatment for
Genitourinary Syndrome of Menopause, studies on video-based education for providers, and
available screening tools for GSM. The databases that were used to search for relevant
information on this topic were The Cumulative Index to Nursing and Allied Health Literature
(CINAHL), Google Scholar, and PubMed. Keywords included the following: genitourinary
syndrome of menopause, estrogen deficiency, hypoestrogenic, vulvovaginal, vaginal atrophy,
dyspareunia, vaginitis, dryness, screening tool, topical estrogen, primary care education, primary
care menopause, provider video education, training. Boolean operators “AND” and “OR” were
used to broaden or narrow the search as applicable.
Inclusion Criteria
For this research study, only primary, peer-reviewed articles were considered. Studies
needed to be written in or translated to English language and include full text. Inclusion criteria
for evidence-based current GSM treatment options consisted of studies published between 2017
and 2022, although older publications were included mainly as a means of outlining the
evolution of GSM knowledge and treatment approaches over time.
Exclusion Criteria
Excluded publications were not primary, peer-reviewed, not published in the English
language and did not include full-text. Additionally, any duplicate articles, editorials or opinion
pieces were excluded from the literature review.

12
Genitourinary Syndrome of Menopause: Treatment
A comprehensive review of current empirical research on genitourinary syndrome of
menopause was conducted to facilitate the creation of a comprehensive, evidence-based
presentation for primary care providers. The treatment of GSM should be addressed with
stepwise fashion and advanced as appropriate based on response (NAMS, 2020). Recommended
interventions will be reviewed in this progressive approach, beginning with first-line treatments.
Personal lubricants and vaginal moisturizers.
According to NAMS, first line therapies for GSM should be over-the-counter, nonhormonal topical treatments, which include lubricants and moisturizers (NAMS, 2020). These
formulations as safest for women for whom hormonal preparations may be contraindicated or
less desirable, such as those with a history of breast cancer or other hormonally-mediated
malignancies (Edwards & Panay, 2015). Lubricants are typically for women whose primary
concern is dyspareunia and increase of comfort during sexual activity, while moisturizers are
utilized to improve overall vaginal tissue hydration and quality regardless of sexual activity
(Edwards & Panay, 2015). These topical applications are typically water, silicone, or oil-based
(Edwards & Panay, 2015). Due to their beneficial qualities, the World Health Organization now
recommends their routine use during sexual activity (World Health Organization [WHO], 2012).
Admittedly, randomized controlled studies on their effectiveness are scarce, although these
topical treatments are generally considered safe (NAMS, 2020).
According to a double-blind prospective study which utilized a daily diary log over a
period of five weeks to test the effectiveness of silicone and water-based lubricants, personal
lubricants are highly effective (Herbenick et al., 2011). A total of 2.453 women were placed in
either the water-based or silicone-based lubricant groups and were asked to record their impact
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on genitourinary symptoms and sexual pleasure (Herbenick et al., 2011). Results revealed that
women in both groups experienced less urogenital symptoms and reported an overall increase in
sexual pleasure, with water-based lubricants being less likely to be associated with irritation
(Herbenick et al., 2011).
In a randomized, double-blind, placebo-controlled study, 86 breast cancer survivors with
induced menopause were randomly assigned to either a placebo group or a vaginal topical gel
group in which they were asked to administer these formulations three times per week for a total
of twelve weeks (Lee et al., 2011). Vaginal dryness and dyspareunia were then measured through
self-reports and vaginal pH measurements and revealed that the vaginal gel offered significant
relief to these women (Lee et al., 2011).
The literature also reports that women generally feel positively about using lubricants
during sexual activity. A cross-sectional study in which 2,451 women were queried about their
perceptions on lubricants revealed that women generally had positive experiences with lubricants
and did not generally report apprehension regarding their use (Jozkowski et al., 2013). In
general, older women tended to report greater satisfaction with these formulations (Jozkowski et
al., 2013). This insight is important when making recommendations about GSM treatment.
As any topical formulation has the potential to cause a reaction, NAMS recommends that
any new application be tested on a small area for 24 hours prior to full use (2020). It is important
to note that the World Health Organization recommends lubricants and moisturizers that are
specially designed for intravaginal use and which meet established pH and osmolarity guidelines
to avoid potential side effects, such as irritation or increased risk of infection (Edwards & Panay,
2015).
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Hyaluronic acid.
Hyaluronic acid is a naturally occurring humectant found in fluids in the eyes and joints
(Liu & Nassim, 2020). These are typically sold over-the-counter as gels or vaginal inserts for
relief of vaginal dryness and several studies have found them effective and safe. Vaginal
hyaluronic acid tends to be more expensive than lubricants or moisturizers, so these may be first
options if cost is an issue.
A double-blind randomized placebo-controlled study measured the efficacy and safety of
a hyaluronic acid gel (Grimaldi et al., 2012). In this study, thirty-six post-menopausal women
were randomly assigned to experimental or controlled groups and were followed over a period of
seven months (Grimaldi et al., 2012). The findings reported significant improvement in
hypoestrogenic vulvovaginal symptoms in both objective and subjective measures (Grimaldi et
al., 2012). Although the sample size was small, it is nevertheless important to note that no
adverse effects were reported during this trial period (Grimaldi et al., 2012).
A randomized controlled trial published in 2011 compared the effectiveness of
hyaluronic acid vaginal tablets versus estrogen vaginal tablets (Ekin et al., 2010).
Another randomized controlled study published in 2013 compared the efficacy and safety
of a hyaluronic acid gel versus an estrogen-based cream (Chen et al., 2013). The study randomly
assigned its 144 subjects to either treatment modality and had them apply their assigned
formulation every three days for a total of thirty days (Chen et al., 2013). The findings revealed
that both applications were highly effective at attenuating vaginal atrophy, with hyaluronic acid
being only slightly less effective than the estrogen cream while retaining a high safety profile
(Chen et al., 2013).
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In a prospective, randomized, double-blind study, researchers compared the efficacy and
safety of vaginal hyaluronic acid with vaginal genistein, a soy-based isoflavone and
phytoestrogen (Le Donne et al., 2010). Genistein is typically used an oral alternative medicine in
the treatment of certain cancers and is not as widely used for vaginal dryness (Le Donne et al.,
2010). In this study, 62 postmenopausal women were randomly assigned to either genistein or
hyaluronic acid groups and asked to use these formulations for fifteen days per month for a total
of three months. At the end of the study, women in both groups reported significant
improvement in both objective and subjective genital symptoms, with genistein vaginal
suppositories showing a clear advantage (Le Donne et al., 2010). According to the authors,
genistein needs further research but represents a hopeful option for the treatment of vaginal
atrophy (Le Donne et al., 2010).
Topical Estrogens
Vaginal estrogen therapies are generally considered the most effective at alleviating
genitourinary symptoms of menopause and are recommended as the therapy of choice when nonhormonal treatments prove insufficiently effective (NAMS, 2020). Estrogen applied vaginally is
minimally absorbed systemically (Santen et al., 2019) and has been shown to be safe for most
women (NAMS, 2020). Nevertheless, NAMS recommends its cautious and carefully considered
use in women with a history of or at risk for estrogen-dependent cancers, and it is
contraindicated in women with undiagnosed postmenopausal bleeding (2020).
Although the use of estrogen in postmenopausal women dropped out of favor following a
2002 Women’s Health Initiative (WHI) study which suggested the risks of hormonal treatments
exceeded the benefits (Rossouw et al., 2002), those results are now widely attributed to
inappropriate extrapolation (Utian, 2015). In fact, a subsequent study by the same group found
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that the benefits of hormonal therapy indeed exceeded its risks in most women (Crandall et al.,
2018). Furthermore, this study showed no increased risk from vaginal estrogen use when
compared to that of the general population (Crandall et al., 2018). More recent studies, including
a 2020 systematic review of randomized controlled trials found that vaginal estrogens did not
pose an increase risk for venous thromboembolic events, an earlier WHI study concern (Crandall
et al., 2020).
Currently and despite the well-regarded safety of vaginal estrogen therapies, the FDA
retains the same black box warnings on these topical formulations as it does on its systemic
therapies, and lists the potential risks of cancers, dementia, and cardiovascular events (NAMS,
2020). As such, NAMS recommends that practitioners educate their patients about the
differences between systemic and localized estrogen (2020).
The effectiveness of vaginal estrogen in treating genitourinary syndrome of menopause is
well documented in evidence-based studies. An early clinical trial found that estrogen delivered
via vaginal ring provided significant relief of urinary and genital symptoms among
postmenopausal women (Nachtigall, 1995). This investigation was soon followed by a
randomized controlled study tested the efficacy of estrogen cream with estrogen vaginal ring
among 194 postmenopausal women with urogenital atrophy (Ayton et al., 1996). This study
found both formulations to be of equal effectiveness (Ayton et al., 1996). At least five more
rigorous studies followed in the following decade supporting this claim (Barentsen et al., 1997;
Casper & Petri, 1999; Henriksson et al., 1994; Lose & Englev, 2000; Weisberg et al., 2005).
Vaginal dehydroepiandrosterone
Dehydroepiandrosterone (DHEA) is a precursor hormone that, when applied topically,
can reduce the urogenital symptoms of menopause (Labrie et al., 2016). In a prospective,
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randomized, double-blind, and placebo-controlled phase III clinical trial, a sample of 482
postmenopausal women were enlisted to test the effects of DHEA on moderate to severe GSM
symptoms (Labrie et al., 2016). The study found DHEA to be highly effective at relieving
localized symptoms and had negligent systemic absorption, leading to an absence of significant
side effects (Labrie et al., 2016).
Ospemifene
Ospemifene is a selective estrogen receptor modulator, and the only oral medication that
is FDA approved for the treatment of GSM. It is available by prescription only (DeGregorio et
al., 2014). This medication has been extensively researched.
One randomized controlled trial followed 304 postmenopausal women on ospemifene for
a full year and found this drug to improve vulvovaginal atrophy and significantly decrease
dyspareunia (Simon et al., 2014). A similar randomized control trial conducted in the same year
corroborated these findings, further noting no episodes of endometrial hyperplasia, cancer, or
cardiovascular events (Eder, 2014). A newer study utilized a retrospective design to evaluate the
efficacy and safety of ospemifene in 39 women with a history of recurrent urinary tract
infections (Schiavi et al., 2017). The results revealed as significant decrease in the incidence of
these infections without reported side effects (Schiavi et al., 2017). In 2019, a randomized,
double-blind, placebo-controlled study further supported the effectiveness of ospemifene in the
treatment of moderate to severe genitourinary symptoms (Archer et al., 2019).
It is interesting to note that, as an estrogen receptor modulator, ospemifene has been
found in laboratory studies to have an inhibitory effect on estrogen-mediated cancer cells,
although studies in this area are still quite limited (Eigeliene et al., 2016). This drug may, then, in
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the future, prove to be an important option for women at risk for cancer who do not respond to
first line treatments but do not wish to pursue estrogen-based therapies.
Provider Video-Based Education
As part of the educational component of this GSM quality improvement project, a video assisted presentation was created to educate primary are providers. This educational modality
was selected after a comprehensive search of current evidence-based literature supported its
efficacy. Video-assisted interventions were shown to be efficient didactic tools for providers,
improving knowledge and increasing targeted screening behaviors, although it is worthy to note
that most studies focused on physicians.
In one cluster randomized controlled trial conducted in Belgium in 2005, researchers
utilized video presentations to educate 36 primary care providers on routine chlamydia screening
and concluded that these educational modalities significantly improved screening for this STI
among these physicians (Verhoeven et al., 2005).
A pre-and post- testing design study utilized an educational video presentation in a
sample of 239 pediatricians and nurses to promote the pediatric visual acuity screening and
found that proper screening increased significantly following this intervention (Clausen et al.,
2009).
A study targeting faculty and medical residents at an academic faculty utilized video
educational series to promote professionalism in the workplace (Farnan et al., 2013). The study
concluded that video-assisted presentations were helpful at promoting civility and decreasing
unprofessional behavior (Farnan et al., 2013).
One study utilized a video-assisted presentation to educate and promote HIV screening
among primary care providers in a publicly-funded healthcare setting (Arya et al., 2018). This
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study utilized a pre- and post-testing design to evaluate video intervention effectiveness (Arya et
al., 2018). The study found that video presentations were effective at improving knowledge on
HIV testing guidelines and enhancing testing in practice (Arya et al., 2018).
Genitourinary Syndrome of Menopause: Screening Tools
Currently, there is no consensus on how to best screen for genitourinary syndrome of
menopause and scholars are urging the development of a unified screening approach (Mension et
al., 2021). One objective tool for evaluating GSM involves the use of the Vaginal health index
(VHI) score, which evaluates observable and/or measurable parameters, such as vaginal pH and
vaginal elasticity (Di Pace & Portuesi, 2018). Although this tool can provide appropriate
objective measures, it may be too invasive for quick screenings, particularly in the primary care
setting. Similarly, an infrequently-used tool is the Vaginal Maturation Index (VMI), which
evaluates GSM based on measurements on vaginal cellular samples (Mac Bride et al., 2010).
The Female Sexual Function Index (FSFI) is a validated tool that focuses specifically on
sexual activity but also addresses lubrication and pain (Sand et al., 2009), two key components in
genitourinary syndrome of menopause.
One tool that has been used to screen for and assess the impact of GSM is the Day-toDay Impact of Vaginal Aging (DIVA) questionnaire. It was developed in 2015 with the aim of
assessing“ the impact of vaginal dryness, soreness, itching, irritation, and pain on functioning
and well-being in postmenopausal women” (Huang et al., 2015). This tool was translated into
Spanish and used in a 2018 cross-sectional study in Spain (Moral et al., 2018). This study
supported the use of the DIVA questionnaire as an effective GSM assessment tool (Moral et al.,
2018). (Archer et al., 2019)Similar reports were obtained in a study conducted earlier this year,
in which this tool was translated into Turkish and validated for use in this cultural group (Sert &
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Özgül, 2022). Another more recent study, a quality improvement project was conducted utilizing
the DIVA questionnaire with the aim for improving identification of GSM among
postmenopausal women (Mastroianni et al., 2020). The study found this tool to be effective and
increasing identification of GSM in a large women’s health practice (Mastroianni et al., 2020).
The DIVA questionnaire also proved effective at identifying vulvovaginal symptoms among
women who had undergone cancer treatment (Toivonen et al., 2021). Overall, studies show the
DIVA questionnaire to be a competent tool in the identification of genitourinary symptoms of
menopause. As such, this tool was selected and introduced to the providers in this study as an
appropriate screening tool option.
Chapter III.
Purpose, PICO Clinical Question, Objectives
Purpose
As primary care is commonly a patient’s principal point of entry into the healthcare
system, providers in this realm need to be well-versed in the identification and management of
genitourinary syndrome of menopause. The purpose of this quality improvement project is to
determine whether a video-assisted educational presentation can improve awareness, knowledge,
and screening of GSM among primary care providers in a large county hospital system in South
Florida.
PICO Clinical Question
Does an informational video-assisted presentation enhance awareness, knowledge, and
screening of genitourinary syndrome of menopause among primary care providers?
P- Primary care providers at a South Florida health system
I- Video-assisted educational presentation
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C-Pre and post intervention surveys
O-awareness, knowledge & screening of GSM
Objectives
The main objective of this project is to improve primary care providers’ awareness,
knowledge, and screening of genitourinary syndrome of menopause.
To support the main objective the SMART criteria was utilized in setting goals for this
DNP project. This mnemonic acronym helps delineate a set of objectives that are specific (S),
measurable (M), achievable (A), relevant (R), and time-bound (T) to successfully guide projects
from planning to completion (Lewis, 2007). The specific objectives for this project utilizing the
SMART criteria are defined below.
Specific
This quality improvement project is designed to educate primary care providers at a
South Florida health system on genitourinary syndrome of menopause, a chronic, life-impacting
condition affecting most menopausal women (NAMS, 2020). This project also provides
comprehensive information on current treatment options and screening guidelines. Additionally,
this project introduces providers to the Day-to Day Impact of Vaginal Aging (DIVA) tool, a
short questionnaire that has been proven effective at screening and identifying cases of GSM
(Mastroianni et al., 2020).
Measurable
This project utilizes pre- and post-test Likert scale surveys to gauge awareness,
knowledge, and screening of GSM before and after a video-enhanced educational presentation.
This information is thus quantifiable and can be measured and analyzed utilizing Qualtrics, a
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robust statistical platform that can help translate data into a meaningful evaluation of the
effectiveness of this educational intervention.
Attainable
The implementation of this project is attainable. An exhaustive presentation was created
utilizing knowledge from published subject experts and leading organizations, such as the North
American Menopause Society (NAMS), all of which are readily available through Florida
International University’s (FIU) academic databases. The primary investigator in this project has
also secured a membership with NAMS, thus facilitating access to additional evidence-based
materials on menopause. Qualtrics, the survey management and data analysis platform utilized
for this project is available free of charge to FIU students, thus not posing a financial
impediment. Additionally, the video-assisted presentation were created with Microsoft
PowerPoint tools, which was readily available to the researcher. The surveys and video
presentation were made available to providers via email links which were accessible 24/7 and
facilitated provider access and participation. The project was also conduced with full
administrative backing from the target health system, a teaching institution in active support of
health research.
Relevant
As previously examined, Genitourinary Syndrome of Menopause is pervasive and has the
potential to broadly impact the physical, emotional, psychosocial, and even financial well-being
of a significant number of menopausal women (Mastroianni et al., 2020). Furthermore, GSM can
lead to increased medical costs and elevated resource utilization and healthcare burden (Assaf et
al., 2017). Despite the availability of very effective therapies, however, GSM remains largely
underdiagnosed and under-treated (Qi et al., 2020). The North American Menopause Society
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(NAMS) urges increased awareness and screening of GSM to narrow the knowledge and
treatment gap (NAMS, 2020). This Quality Improvement project is relevant, as it aims to bring
attention to GSM and improve its management at women’s main entry point in the healthcare
system.
Time Bound
This project ran from January 2022 to November 2022, during which time it adhered to
timelines and deadlines to guide it to successful completion. Adjustments were made only when
necessary to accommodate institutional review processes and schedules.
Organizational Assessment and SWOT Analysis
Organizational Assessment
This quality improvement project took place at a large South Florida county health
system. This non-profit academic tertiary care medical systems consists of several hospitals
throughout the county and a network of outpatient primary care and specialty care clinics and
urgent care centers.This institution is committed to providing high quality medical care for all
persons who walk through its doors, regardless of residency, legal, or financial status, but is
primarily focused on serving those living within the county borders. The city it serves is co
prised of 65% Hispanic residents, 16.8% Black, non-Hispanic, and 15.1% white, non-Hispanic,
making it a unique minority majority population (Health Council of South Florida [HCSF],
2018). This city’s population is impacted by significant health and socioeconomic disparities,
with 30% of African American residents and 20% of Hispanic residents living in poverty,
compared to 11.6% of white non-Hispanics (HCSF, 2018). On its most recent Community
Health Needs Assessment report, this health system identified several key priority areas
requiring immediate attention: Availability of primary care and prevention, access to care,
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chronic disease management, maternal and child care, and healthy lifestyles (HCSF, 2018).
Keeping in line with these priority areas and in alignment with their mission to provide a single
high-standard quality of care and to improve the health of the community (Jackson Health
System [JHS], n.d.-a), this DNP project focuses on educating and updating primary care
providers on genitourinary syndrome of menopause (GSM), a newly-minted, chronic and undertreated condition that impacts the health and well-being of the majority of menopausal women
(NAMS, 2020). In this project, the main organizational targets consist of this health system’s
nine primary care clinics, which are currently staffed by twenty Internal and Family Medicine
physicians, seven Adult and Family nurse practitioners, and one Physician Assistant. These
providers care for predominantly underserved populations, typically >50% female, and currently
manage an average of over 120,000 clinic visits per year (HCSF, 2018). Currently, there is no
routine screening for GSM among primary care providers at these clinics. In their most recent
position statement, North American Menopause Society (NAMS) has recommended provider
education and routine assessment for GSM in order to narrow the knowledge and treatment gap
that is currently prevalent (2020). Providing GSM education to primary care providers in this
health system thus represents a unique opportunity to help reduce disparities and improve the
lives of afflicted women in South Florida, while supporting this health system’s vision of health
equality.
SWOT Analysis
To ensure the appropriateness and feasibility of this quality improvement project, a
SWOT analysis was conducted to evaluate the relevant strengths, weaknesses, opportunities, and
threats at the target health system.

25
The main organizational strength of this health system is its size and ubiquitous presence
as a health provider in South Florida. As previously mentioned, providers in this system conduct
over 100,000 clinic visits every year and thus quality improvement projects have the potential to
make a significant impact on the health and well-being of its citizens. Additionally, this health
system is a teaching institution that encourages and support a vibrant research community.
Creating a QI project in this setting is consistently met with encouragement and approval.
Another important strength is this system’s commitment to improve healthcare and reduce health
disparities among those served. This QI project is thus well-aligned with this pledge.
One important weakness identified was the high caseload that each primary care provider
has each day. On most days, each PCP has a panel with up to 26 scheduled patients. Although
this volume is an advantage in terms of population impact, it may also prove to be a weakness
given the limited time available to evaluate each patient and the possible provider reluctance to
add additional screening items for every qualifying woman. These same time constraints could
also impact completion of surveys and viewing of an educational presentation that is not
mandated.
This QI project offers important opportunities for this health system. Increasing
awareness and screening of GSM can help it meet current recommended guidelines and meet its
own goals of narrowed health disparities. A focus on issues that are important to women can also
serve to elevate this health system’s community standing and attract additional customers,
making it more competitive in the tough healthcare market.
A potential threat identified would be liability related to treatment recommendations.
Topical hormonal treatments are one of the main therapies for GSM. Although topical
formulations have been extensively studies and deemed safe for most women, there are some
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women for whom estrogen may be contraindicated (NAMS, 2020). As such, it would be
essential to ensure thorough provider education.
Table 1
SWOT Analysis of the South Florida health system
Strengths
•Strong community presence
•Commitment to reduce health disparities
•Teaching institution

Weaknesses
•High PCP caseload volume
•Provider time constraints

Opportunities
•Help health system meet current recommended guidelines
•Reduce health disparities
•Support women’s health

Threats
•Therapy contraindications
•Liability concerns

Chapter IV.
Definition of Terms
Menopause: The period in a woman’s life that marks the end of the childbearing years. It
typically occurs between the ages of 45-55 and is defined as the cessation of menses for at least
12 consecutive months. Menopause can also be artificially induced prematurely through the
surgical removal of the ovaries or by certain medical treatments (chemotherapy/radiation) or
medical conditions or infections (Santen et al., 2014).
Perimenopause: This is the transitional period that precedes menopause. During this time,
estrogen levels begin to decrease and can fluctuate significantly. Symptoms like skipped periods
and hot flashes may be experienced during this time. This transition period can last many years
(Delamater & Santoro, 2018).
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Genitourinary Syndrome of Menopause (GSM): Newly-coined term that encompasses the
progressive genital and urinary symptoms that are directly related to a woman’s hypoestrogenic
state of menopause (NAMS, 2020).
Hypoestrogenic: Refers to low levels of estrogen in the body, a main characteristic of
menopause (Gandhi et al., 2016).
Atrophic vaginitis: Refers to the chronic thinning, drying and inflammation of the vaginal
tissues as a result of hypoestrogenic states (Sobel & Sobel, 2014).
Dyspareunia: Genital pain before, during, or after intercourse (Belardo, 2021).
Chapter V.
Conceptual Underpinning and Theoretical Framework of the Project
The Theory of Planned Behavior (TPB) is a social cognitive theory which has been used
extensively to support education and interventions that enhance guideline adherence among
medical providers (Liang et al., 2017) and was used to guide the design and implementation of
this DNP project. This theory views individuals as engaged participants who actively process
available information before committing to intentions that guide behavior (Ajzen, 1991). These
intentions are shaped by three central variables: Attitude, subjective norms, and perceived
behavioral control (Ajzen, 1991). Attitude involves the rational assessment or beliefs about a
particular behavior based on existing knowledge and exposure to information (Ajzen, 1991).
Subjective norms (social pressure) are based on the perception of others’ beliefs about a
particular behavior and are impacted by the human proclivity to gain another’s approval.
Perceived behavioral controls (PBC) relate to a person’s judgment on the ease or difficulty of
performing certain behaviors (Ajzen, 1991). Utilizing the tenets of the Theory of Planned
Behavior, this project introduces a video-enhanced educational presentation on GSM and its
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impact, the latest evidence-supported treatment information, screening recommendations, and
introduction of a screening tool that can be readily used in clinical practice. The assumption is
that the information provided can help heighten and expand a provider’s perspective or attitude
towards GSM, which, according to the TPB, is a crucial first step in enacting change. Through
this presentation, providers would gain insight into the plight of afflicted women, their
compelling need for care, and the urgent endorsement for GSM screening by the North American
Menopause Society. Guided by the TPB, this insight can be viewed as an awareness of the
subjective societal norms which are the second important influencer of intention and predictor of
change. As guideline adherence is often hindered by provider time constraints (Khatib et al.,
2014), the introduction of a simple screening tool should positively impact perceived behavioral
control, which is the TPB’s final variable in predicting the likelihood that a behavior (in this
case, GSM screening), will actually take place. The Theory of Planned Behavior provides a
useful framework to steer this project from design to successful completion.
Chapter VI.
Methodology
Study Design
This quality improvement project utilized a quasi-experimental pre-test, post-test design
to assess the value of an educational video-assisted presentation.
Setting
This QI project was conducted across nine outpatient primary care clinics at a large South
Florida health system. These clinics serve insured, underinsured, and uninsured clients, and are
particularly focused on serving the underserved.
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Participants
The participants were primary care providers. Twenty-seven providers, including twenty
Internal and Family Medicine physicians, seven Adult and Family nurse practitioners, and one
Physician Assistant were recruited and a total of twelve (n=12) participants completed all three
parts of this quality improvement intervention (pretest, educational video presentation, and
posttest.)
Intervention
The first step in this project was securing the support of the targeted institution. This
Letter of Institutional Support can be found in Appendix A. This first step allowed the DNP
student to commence the formal steps of securing approval from both academic and health care
institutions involved. The project proposal was presented to Florida International University and
an Institutional Review Board Exemption was granted. This document can be located in
Appendix B. Following this approval, formal steps were taken to secure approval from target
health institution. Two approvals were obtained from the target South Florida health system: JHS
Nursing Research & Evidence-based Practice Council (NREBPC) and CNO Council Approval
Letter, found in Appendix C; and JHS Clinical Trials Office Approval Letter, found in Appendix
D. Once all formal approvals had been secured, the DNP student began the recruitment of
primary care providers at target institution via organizational email. This recruitment email
introduced the DNP student and provided information about the QI project. Providers who
agreed to participate in this study could then choose to access the Qualtrics pretest survey,
YouTube informational video, and Qualtrics posttest survey directly from this email. Providers
had access to this study for a two-week period. Reminders were sent during this time to
encourage provider participation.
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Instruments
Eleven-point Likert scale pretest and posttest surveys were utilized via Qualtrics to gauge
three main research concepts: awareness (3 questions), knowledge (6 questions), and screening
(1 question) of genitourinary syndrome of menopause among primary care providers before and
after a 40-minute educational video-assisted presentation. An additional question in the pre-test
and posttest surveys gauged the effectiveness of the introduction of a GSM screening tool during
the presentation and was not tied to any of the three main research concepts. The educational
intervention consisted of a forty-minute video-assisted PowerPoint presentation on GSM,
including background, impact on women, and significance of treatment gap. It also provided a
review of current evidence-based treatment options in stepwise fashion, including over-thecounter formulations, followed by prescription topical non-hormonal, oral, and topical hormonal
treatment modalities. Statistical analysis of pretest and posttest data was conducted with the aid
of GraphPad Prism version 9.4.1 by Dotmatics.
Data Collection
Recruitment emails were sent to primary care providers at the target South Florida health
system by the DNP candidate. This email provided potential participants with information about
the quality intervention project, including purpose, steps required for participation, approximate
time commitment, privacy protections, and potential risks and benefits. The email also advised
providers that they were under no obligation to partake in study, and that there would be no cost
or payment should they opt to participate. Providers who chose to be included in this project
could access study directly through recruitment email. Links were provided to Qualtrics pretest
and posttest surveys to assess GSM awareness, knowledge and screening, as well as link to fortyminute YouTube educational video presentation on GSM. All surveys were anonymous and no
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personal or identifying information was collected. Surveys were utilized to gauge impact of
educational intervention on providers’ awareness, knowledge, and screening of genitourinary
syndrome of menopause.
Data Analysis
Collected data was analyzed using GraphPad Prism version 9.4.1.by Dotmatics.
Collective Likert responses were grouped by concept and scored with a percentage and mean
was calculated. Paired t-tests were used to compare mean awareness and knowledge, while
unpaired t-test was used to compare screening impact. An additional unpaired t-test was utilized
to calculate familiarity with Day-to-Day Impact of Vaginal Aging (DIVA). For all topic
domains, t-values and p-values were obtained. A conventional alpha level of 0.05 was used for
all statistical calculations.
Protection of Human Subjects
All investigators in this study completed and received certification for the Collaborative
Institutional Training Initiative (CITI) program training, which focuses on the ethical and
responsible research of human subjects. The project was reviewed by Florida International
University’s Institutional Review Board and, as no patients were participating, received an
exemption on August 16, 2022. The project was also reviewed and approved by the target health
system’s Nursing Research & Evidence-Based Practice Council, Chief Nursing Officers Council
(CNOC), and Clinical Research Review Committee (CRRC). The subjects of this study were
primary care providers. They were advised that participation was strictly voluntary, with no
penalty attached for not taking part in this project. They were also advised they could withdraw
at any time. Participants were provided with a brief introduction to the project via email, prior to
introducing the pre-test survey. This introduction detailed the purpose of the study, the steps
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required to complete it, and the likely timeframe required for completion. Participants remained
anonymous and no personal or identifying information was collected. Data was collected via
Qualtrics, which utilizes Transport Layer Security (TLS) encryption. All data was kept private in
a password and spyware-protected laptop in locked cabinet. Only investigators in this study had
access to data.
Benefits
The main benefit of this Quality Improvement project was to enhance provider
awareness, knowledge, and screening of genitourinary syndrome of menopause. It is expected
that this enhancement will, in turn, benefit society by helping reduce the GSM treatment gap,
improving the health and well-being of afflicted women and optimizing their societal
engagement, and by reducing the financial and healthcare burden of untreated GSM.
Risks
Participants are not expected to experience any risks, harms, and/or discomforts through
participation in this project. There are no costs or obligations and providers may withdraw from
study at any time.
Chapter VII.
Results
The purpose of this quality improvement project was to evaluate the effectiveness of a
video-assisted educational presentation on primary care providers’ awareness, knowledge, and
screening of genitourinary syndrome of menopause. Twenty-seven providers aware invited to
participate in this study. A total of twelve (n=12) completed the pretest survey, educational
presentation, and posttest survey.
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Pre- and Post-Intervention Results
Awareness
Pre-intervention. The first concept assessed in this study was awareness of genitourinary
syndrome of menopause. This concept was measured utilizing three Likert statements (#1, #2,
and #3 in pre- and posttest surveys). A total of 12 providers answered all items. Prior to
intervention, 8.33% (n=1) of providers strongly agreed and 33.33% (n=4) agreed with their
familiarity with genitourinary syndrome of menopause. A total of 16.67% (n=2) were neutral on
the subject, while a total of 41.67% (n=5) were unfamiliar with GSM. A total of 33% (n=4)
strongly agreed and 41.67% (n=5) agreed that GSM should be routinely addressed and treated in
the primary care setting. A total of 25% (n=3) were neutral on the subjects, while no providers
disagreed with the importance of GSM management. Of the twelve participants, 8.33% (n=1)
strongly agreed and 50% (n=6) agreed they were familiar with the impact of GSM on afflicted
women, the healthcare system, and society in general. Of this sample, 8.33% (n=1) of
participants disagreed and 8.33% (n=1) strongly disagreed with this statement.
Post-intervention. Following the video presentation, 83.33% (n=10) strongly agreed and
16.67% (n=2) agreed that they were familiar with the term GSM. No providers were neutral or
disagreed with this statement. After the presentation, a total of 75% (n=9) strongly agreed and
25% (n=3) agreed that it was important to routinely address and manage GSM in primary care.
No providers were neutral or disagreed with this statement. Similarly, a total of 75% (n=9)
strongly agreed and 25% (n=3) agreed that they were familiar impact of GSM on afflicted
women, the healthcare system, and society.
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Table 2
Participant’s awareness of genitourinary syndrome of menopause
Question
Pre-Intervention
Post-Intervention
(n=12)
(n=12)
I am familiar with the term
Genitourinary Syndrome of
Menopause (GSM)
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree

% Change

1 (8.33%)
4 (33.33%)
2 (16.67%)
5 (41.67%)
0 (0%)

10 (83.33%)
2 (16.67%)
0 (0%)
0 (0%)
0 (0%)

80.0 ↑
16.66 ↓
16.67 ↓
41.67 ↓
0

4 (33.33%)
5 (41.67%)
3 (25%)
0 (0%)
0 (0%)

9 (75%)
3 (25%)
0 (0%)
0 (0%)
0 (0%)

41.67 ↑
16.67 ↓
25↓
0
0

1 (8.33%)
6 (50%)
3 (25%)
1 (8.33%)
1 (8.33%)

9 (75%)
3 (25%)
0 (0%)
0 (0%)
0 (0%)

66.67 ↑
25 ↓
25 ↓
8.33 ↓
8.33 ↓

I feel that GSM should be routinely
addressed and treated in the
primary care setting.
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree
I am familiar with the impact of
GSM on afflicted women, the
healthcare system, and society in
general.
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree
Note: *= correct answer
Awareness Paired Sample t-Test.
A two-tailed paired sample t-test was used to determine if the mean difference of
awareness of GSM from the pre- and post- intervention scores was significantly different from
zero. The result of the two-tailed paired sample t- test was not statistically significant based on
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an alpha value of 0.05, t= 3.2778, and p=0.0818. The findings suggest the mean difference from
the pre- and post- survey was not significantly different from zero. In summary, there was no
statistically significant change in awareness among primary care providers following educational
video presentation. The results are presented in Table 3.
Table 3
Awareness paired t test results
Pre-Intervention Post-Intervention
t value
Mean
3.33
3.08
SD
0.22
1.2

0.2983

P-Value

0.7936

Knowledge
Pre-intervention. The second concept assessed in this study was knowledge of
genitourinary syndrome of menopause. This concept was measured utilizing six Likert
statements (#6, #7, #8, #9, #10, and #11 in pre- and posttest surveys). A total of 12 providers
answered all items. Prior to video presentation, 25% (n=3) strongly agreed and 50% (n=6)
agreed they were confident in their knowledge of OTC options for management of GSM. There
was a total of 8.33% (n=1) who was neutral and 8.33% (n=1) and 8.33% (n=1) who disagreed
and 8.33% (n=1) who strongly disagreed with this statement. When querying for confidence in
knowledge of prescription non-hormonal topical treatments for management of GSM, no
providers reported strong agreement, 8.33% (n=1) while only 8.33% (n=1) agreed with this
statement. A total of 41.67% (n=5) were neutral, while 41.67% (n=5) disagreed and 8.33% (n=1)
strongly disagreed with this statement. Similarly, when measuring confidence in knowledge of
prescription non-hormonal oral treatments for GSM, no providers reported strong agreement,
while 33.33% (n=4) agreed with this statement. A total of 33.33% (n=4) were neutral in this
area, while 16.67% (n=2) disagreed and 16.67% (n=2) strongly disagreed with this statement, or
were not confident on their knowledge of prescription non-hormonal oral treatment options. The
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results were slightly better for confidence in my knowledge of prescription hormonal topical
treatments for GSM, where 33.33% (n=4) agreed they were confident. However, 33.33% (n=4)
were neutral, and 33.33% (n=4) disagreed and 16.67% (n=2) strongly disagreed they were
knowledgeable about prescription hormonal topical treatments. When asked if they were familiar
with current guidelines on the safe use of topical hormonal treatments for GSM, no providers
strongly agreed with this statement, while 25% (n=3) agreed. Half of providers (n=6) were
neutral, while 8.33% (n=1) disagreed and 16.67% (n=2) strongly disagreed with this statement.
When queried about overall confidence in ability to effectively address GSM, no providers were
in strong agreement, 16.67% (n=2) were in agreement, 58.33% (n=7) were neutral, while 8.33%
(n=1) disagreed and 16.67% (n=2) strongly disagreed with this statement, or were not confident
in their ability to manage GSM.
Post-intervention. Following the video presentation, 83.33% (n=10) of providers
strongly agreed they were confident in my knowledge of OTC options for management of GSM.
A total of 16.67% (n=2) agreed, while no providers were either neutral or disagreed with this
statement. A similar change was reported post intervention on confidence regarding knowledge
of prescription non-hormonal topical treatments, where 75% (n=9) showed strong agreement,
while 25% (n=3) showed agreement with this statement. No providers were neutral or disagreed
with this statement. When reporting confidence in knowledge of prescription non-hormonal oral
treatments for GSM, 75% (n=9) strongly agreed and 8.33% (n=1) agreed with this statement, and
16.67% (n=2) were neutral. No providers reported lack of confidence in knowledge of
prescription non-hormonal oral treatments. Post intervention, confidence on knowledge of
prescription hormonal topical treatments for GSM increased, with 75% (n=9) strongly agreeing
and 16.67% (n=2) agreeing they were confident in their knowledge, while 8.33% (n=1) was
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neutral. There were no providers who were not confident on their knowledge of prescription
hormonal topical treatments. Familiarity with current guidelines on the safe use of topical
hormonal treatments for GSM increased post intervention, with 66.66% (n=8) showing strong
agreement and 25% (n=3) showing agreement with confidence level. A total of 8.33% (n=1)
were neutral, and no providers reported lack familiarity with current guidelines. Finally, general
confidence on ability to effectively address GSM increased, with 58.33% (n=7) reporting strong
agreement and 25% (n=3) reporting agreement. A total of 16.67% (n=2) were neutral, and no
providers reported lack of confidence in their overall ability to manage GSM.
Table 4
Participant’s knowledge of genitourinary syndrome of menopause
Question
Pre-Intervention
Post-Intervention
(n=12)
(n=12)
I am confident in my knowledge of
OTC options for management of
GSM.
3 (25%)
10 (83.33%)
Strongly agree *
6 (50%)
2 (16.67%)
Agree
1 (8.33%)
0 (0%)
Neutral
1 (8.33%)
0 (0%)
Disagree
1 (8.33%)
0 (0%)
Strongly Disagree
I am confident in my knowledge of
prescription non-hormonal topical
treatments for management of
GSM.
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree
I am confident in my knowledge of
prescription non-hormonal oral
treatments for GSM.

% Change

58.33 ↑
33.33 ↓
8.33 ↓
8.33 ↓
8.33 ↓

0 (0%)
1 (8.33%)
5 (41.67%)
5 (41.67%)
1 (8.33%)

9 (75%)
3 (25%)
0 (0%)
0 (0%)
0 (0%)

75 ↑
16.67 ↑
41.67 ↓
41.67 ↓
8.33 ↓

0 (0%)
1 (8.33%)

9 (75%)
1 (8.33%)

75 ↑
0
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Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree
I am confident in my knowledge of
prescription hormonal topical
treatments for GSM.
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree
I am familiar with current
guidelines on the safe use of topical
hormonal treatments for GSM.
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree
In general, I feel confident in my
ability to effectively address GSM
with my patients.
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree

1 (8.33%)
6 (50%)
4 (33.33%)

2 (16.67%)
0 (0%)
0 (0%)

8.34 ↑
50 ↓
33.33 ↓

0 (0%)
4 (33.33%)
4 (33.33%)
2 (16.67%)
2 (16.67%)

9 (75%)
2 (16.67%)
1 (8.33%)
0 (0%)
0 (0%)

75 ↑
16.66 ↓
25 ↓
16.67 ↓
16.67 ↓

0 (0%)
3 (25%)
6 (50%)
1 (8.33%)
2 (16.67%)

8 (66.66%)
3 (25%)
1 (8.33%)
0 (0%)
0 (0%)

66.66 ↑
0
41.67 ↓
8.33 ↓
16.67 ↓

0 (0%)
2 (16.67%)
7 (58.33%)
1 (8.33%)
2 (16.67%)

7 (58.33%)
3 (25%)
2 (16.67%)
0 (0%)
0 (0%)

58.33 ↑
8.33 ↑
41.66 ↓
8.33 ↓
16.67 ↓

Knowledge Paired Sample t-Test.
A two-tailed paired sample t-test was used to determine if the mean difference of
knowledge of GSM from the pre- and post- intervention scores was significantly different from
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zero. The result of the two-tailed paired sample t- test is considered to be very statistically
significant based on an alpha value of 0.05, t= 4.5110, and p=0.0063. The findings suggest the
mean difference from the pre- and post- survey was significantly different from zero. The results
indicated that there was a significant change in GSM awareness post-intervention. The results are
presented in Table 5.

Table 5
Knowledge paired t test results
Pre-Intervention Post-Intervention
t value
P-Value
Mean
2.76
3.88
4.5110
0.0063
SD
0.59
0.08
Screening
Pre-intervention. The third concept assessed in this study was screening of genitourinary
syndrome of menopause. This concept was measured utilizing one Likert statement (#5 in preand posttest surveys). A total of 12 providers complete this item. Prior to intervention, providers
were asked to report their level of agreement with their regular screening for GSM. No providers
were in strong agreement, while 16.67% (n=2) were in agreement. Half of providers (n=6) were
neutral, and 25% (n=3) disagreed and 8.33% (n=1) strongly disagreed that they regularly
screened for GSM.
Post-Intervention. After the educational presentation, providers were asked if they
would regularly screen for GSM, and a total of 66.66% (n=8) strongly agreed and 25% (n=3)
agreed they would. Only 8.33% (n=1) were neutral, while no providers disagreed on plans to
screen for GSM.
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Table 6
Participant’s screening of genitourinary syndrome of menopause
Question
Pre-Intervention
Post-Intervention
(n=12)
(n=12)
I regularly screen or plan to
routinely screen for GSM in my
current practice.
0 (0%)
8 (66.66%)
Strongly agree *
2 (16.67%)
3 (25%)
Agree
6 (50%)
1 (8.33%)
Neutral
3 (25%)
0 (0%)
1 (8.33%)
0 (0%)
Disagree
Strongly Disagree

% Change

66.66 ↑
8.33 ↑
41.67 ↓
25 ↓
8.33 ↓

Note: *= correct answer
Screening Unpaired Sample t-Test.
An unpaired sample t-test was used to determine if the mean difference of screening for
GSM in the pre- and post- intervention scores was significantly different from zero. The result of
the unpaired sample t- test is considered to be statistically significant based on an alpha value of
0.05, t= 2.1424, and p=0.0435. The findings suggest the mean difference from the pre- and postsurvey was significantly different from zero. The results are presented in Table 7.
Table 7
Screening unpaired t test results
Pre-Intervention Post-Intervention
t value
P-Value
Mean
2.75
3.92
2.1424
0.0435
SD
0.83
1.70
Familiarity with the DIVA Questionnaire
Pre-intervention. As described in the Instruments section of this paper, the genitourinary
syndrome of menopause presentation also introduced providers to the screening tool, Day-to-Day
Impact of Vaginal Aging (DIVA) questionnaire. This effectiveness of this introduction was
assessed with one Likert statement (#4 in pre- and posttest surveys). A total of 12 providers

41
completed this item. Prior to the introduction, no providers agreed they were familiar with this
tool. A total of 8.33% (n=1) were neutral, while 16.67% (n=2) disagreed and 75% (n=9) strongly
disagreed on their familiarity with this tool.
Post-intervention. Following the introduction of this tool, 75% (n=9) of providers
strongly agreed and 25% (n=3) agreed they were familiar with this tool. No providers were
neutral or reported disagreement with their familiarity with the DIVA questionnaire.
Table 8
Familiarity with Day-to-Day Impact of Vaginal aging (DIVA) questionnaire
Question
Pre-Intervention
Post-Intervention
(n=12)
(n=12)
I am familiar with the Day-to Day
Impact of Vaginal Aging (DIVA)
questionnaire
Strongly agree *
Agree
Neutral
Disagree
Strongly Disagree

0 (0%)
0 (0)
1 (8.33%)
2 (16.67%)
9 (75%)

9 (75%)
3 (25%)
0 (0%)
0 (0%)
0 (0%)

% Change

75 ↑
25 ↑
8.33 ↓
16.67 ↓
75 ↓

Note: *= correct answer
Familiarity with DIVA Questionnaire Unpaired Sample t-Test.
An unpaired sample t-test was used to determine if the mean difference of familiarity
with DIVA questionnaire in the pre- and post- intervention scores were significantly different
from zero. The result of the unpaired sample t- test is considered to be extremely statistically
significant based on an alpha value of 0.05, t= 4.2209, and p=0.0004. The findings suggest the
mean difference from the pre- and post- survey was significantly different from zero. The results
indicated that providers were effectively familiarized with this screening tool during the
presentation. The results are presented in Table 9.
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Table 9
Familiarity with DIVA questionnaire unpaired t test scores
Pre-Intervention Post-Intervention
Mean

1.33

3.80

SD

0.62

1.93

t value

P-Value

4.2209

0.0004

Chapter VIII.
Discussion
The overall results from this quality improvement project reveal that an educational video
intervention can improve knowledge and screening of genitourinary syndrome of menopause
among primary care providers. The most consequential change occurred in the level of
knowledge post intervention. Prior to the video presentation, providers were relatively confident
in their knowledge of over-the-counter treatment options about GSM, but a majority were either
neutral or not confident in their level of knowledge regarding prescriptions non-hormonal topical
treatments, prescription non-hormonal oral treatments, and prescription hormonal topical
treatments. Additionally, most provider were either neutral or not confident in their knowledge
of current guidelines for safe use of topical hormonal treatments or their overall knowledge of
GSM management. Following the educational video presentation, results from paired t-tests
revealed a very statistically significant change, confirming improved knowledge across the
board. All providers either agreed or strongly agreed that they felt confident in their knowledge
of over-the-counter treatments and prescription non-hormonal topical treatments. Similarly, a
majority of providers agreed or strongly agreed they felt confident in their knowledge of nonhormonal oral treatments and prescription hormonal topical treatments. A small minority were
neutral, and no providers reported feeling a lack of confidence in their GSM knowledge of these
treatment options. Most providers also agreed or strongly agreed that they felt confident in their
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knowledge of current guidelines safe use of topical hormonal treatments (91% compared to
33.33% prior to intervention), and a majority of providers felt generally more confident in their
overall knowledge of GSM management (60.33% compared to 16.67% prior to intervention). No
providers reported lack of confidence in their overall knowledge of GSM management.
According to the results of paired t-test analysis, there was also a statistically significant
improvement in GSM screening after video presentation. Prior to intervention, only 16.67% of
providers agreed that they regularly screened for GSM, while 91.66% planned to screen for GSM
after watching video. The significant improvement in this area is particularly important, as
screening for genitourinary syndrome for menopause represents an essential step in helping
reduce the current treatment gap ((NAMS, 2020).
The only concept measured in this study that did not demonstrate a significant
improvement post intervention was awareness of GSM. In general, this group of providers
agreed with the importance of routine management of GSM and were familiar with GSM impact
on afflicted women, the healthcare system, and society in general. Although the change was not
significant, there was an overall increase in provider awareness of GSM after watching the
educational video.
The results from this quality improvement study are encouraging and point to the value of
dedicated education on genitourinary syndrome of menopause in increasing provider awareness,
knowledge, and screening of this currently underdiagnosed and under-treated condition.
Chapter IX.
Limitations
There was important information gained from this quality improvement project, but there
were also several limitations that were identified that may have impacted the final results. The
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most notable limitation was small sample size. For this study, a total of twenty-seven providers
were recruited, but only twelve completed all required steps. This may be partly due to the
limited time frame which was granted for completion of the study. Originally, the DNP student
had planned to provide access to surveys and educational presentation for a four-week period.
However, delays in IRB approvals and institutional permissions made it necessary to abbreviate
this time-frame. Another factor that may have impacted participation was the time commitment
required from each provider. The video presentation was 40-minutes long and each of the two
surveys could take up to five minutes to complete. A fifty-minute time commitment for busy
providers who were only granted a limited time-frame to access the study may have restrained
engagement. There is also evidence that interest and attention during a medical presentation can
drop significantly after the 15-20 minute mark (Bordes et al., 2020), so the length of this study’s
video intervention may have disengaged providers who may have otherwise been ready to
participate.
Another limitation of this study is the lack of demographics of participants. While all
subjects were primary care providers, a breakdown of educational background (NP, PA, MD),
length of experience, and even age and sex may have provided important insight into the
knowledge gaps and management of genitourinary syndrome of menopause among a variety of
provider groups.
The pre- and post-test surveys utilized for this research study were simple Likert scale
tools designed to quickly ascertain a change in awareness, knowledge, and screening of GSM.
These tools, however, were not tested for validity or reliability. Additionally, the lack of a
control group limits the relevance of the study’s final results.
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One final limitation in this study is the introduction of only the English version of the
Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire. Efforts were made to secure the
validated Spanish version of this tool without success. Screening for GSM in various languages
would be of crucial importance to ensure health equity for all women.
Chapter X.
Implications for Advanced Nursing Practice
The health and well-being of women are undeniably important; thus, the current GSM
treatment gap represents a regrettable discrepancy in the health care system. The results of this
QI project demonstrates that a knowledge gap is indeed present and that providers can greatly
benefit from interventions that aim to improve their women’s health knowledge. Genitourinary
syndrome of menopause, in particular, requires dedicated attention given its pervasive impact.
Several renowned organizations, including the North American Menopause Society and the
International Society for the Study of Women’s Sexual Health are advocating for the
destigmatization of menopause and call for increase education on GSM (NAMS, 2020). An
important first step in improving identification and treatment of GSM would be to establish GSM
education in advanced nursing practice curriculums. In this manner, nurse practitioners can be
ready and poised to make a positive impact on the lives of perimenopausal and menopausal
women as soon as they enter the healthcare system. Additionally, healthcare institutions should
offer regular education and refreshment courses on GSM management. Lastly, regular screening
protocols could be established to further ensure GSM does not go unnoticed or untreated.
Dissemination and Sustainability
Nurse practitioners, particularly those at the doctoral level, have a responsibility to
contribute to public health not just through clinical practice, but also through clinical leadership,
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improvement of healthcare systems, and dissemination of evidence-based research. In alignment
with this commitment to enhance healthcare outcomes, this QI project was presented at the
Nurse Practitioner Council Meeting “Strategies to Strengthen Healthcare Delivery Through
Quality Improvement Initiatives” (Goldin et al, 2022), and will also be presented to the South
Florida healthcare system targeted for this study. A case will be made to this institution’s
Nursing Research & Evidence-Based Practice Council, Chief Nursing Officers Council (CNOC),
and Clinical Research Review Committee (CRRC) for the regular education of primary care
providers on the topic of genitourinary syndrome of menopause. In this manner the positive
results obtained from this small sample of providers can be expanded and sustained over time.
Finally, an abstract for this QI project will be presented for consideration at FNA conferences in
the upcoming year.
Chapter XI.
Conclusion
Genitourinary Syndrome of Menopause is an underdiagnosed and under-treated disorder
that impacts the health and well-being of most menopausal women. This chronic, progressive,
and life-impacting condition can dramatically alter a woman’s well-being, quality of life, and
productivity. If untreated, it can also significantly increase the burden of care on an already
strained medical system. The QI project presented in this paper showed very promising results
on the value of GSM education among primary care providers. A future larger-scale study can
offer more comprehensive and meaningful judgment on the impact of this education. Follow-up
studies can also help determine the long-term impact and tenability of this training. In the
meantime, this small study offers support for the importance of dedicated GSM education.
Through increased awareness, knowledge, and screening of GSM, nurse practitioners and other
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primary care providers can be well poised to reduce treatment gaps among afflicted women,
helping decrease health disparities and medical costs. Most importantly, primary care providers
who are knowledgeable on GSM management can help significantly enhance the health and
well-being of women during the menopausal years.
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Appendix E
Informational Letter
Effectiveness of an Informational Video-Assisted Presentation on Primary Care
Provider Awareness, Knowledge, and Screening of Genitourinary Syndrome of
Menopause: A Quality Improvement Project
Hello, my name is Patricia Diaz, APRN, MSN, DNP student. You have been chosen to be
in a research study about genitourinary syndrome of menopause management in the primary care
setting. The purpose of the study is to increase genitourinary syndrome of menopause (GSM)
awareness, knowledge, and screening and determine the efficacy of a video-assisted PowerPoint
educational presentation to meet these objectives.
Participation in this study will take between 45-50 minutes of your time. If you agree to
be in the study, I will ask you to do the following things:
1. Complete a pre-test survey to gauge current awareness, knowledge, and screening
practices of GSM. This pre-test is expected to take 2-5 minutes of your time.
2. Watch an educational video-assisted PowerPoint presentation on GSM, including
recommendations for screening and current evidence-based treatment options. This
presentation will also introduce a GSM screening tool that may be utilized in practice.
This presentation will take 40 minutes of your time.
3. Complete a post-test survey to assess impact of presentation. This post-test is expected to
take 2-5 minutes of your time.
4. Pre-test and post-test surveys as well as educational presentation will be made available
via electronic link. The survey questions will be administered and analyzed via Qualtrics,
a secure data management company, and you will remain anonymous.
There is no cost or payment to you. There are no foreseeable risks for participating in this
study. Potential benefits to participants include improved awareness and knowledge of
genitourinary syndrome of menopause. It is expected that this increased awareness and
knowledge will, in turn, benefit society by helping reduce the GSM treatment gap, enhancing the
health and well-being of afflicted women and optimizing their societal engagement, and reducing
the financial and healthcare burden of untreated GSM.
If you have questions for one of the researchers conducting this study, you may contact
the primary investigator Dana Sherman, DNP, ARNP, ANP-BC at (305) 348-2247, FNP-BC or
Patricia Diaz, APRN, MSN, DNP student at (305) 776-6935.
If you would like to talk with someone about your rights of being a subject in this
research study or about ethical issues with this research study, you may contact the FIU Office of
Research Integrity by phone at 305-348-2494 or by email at ori@fiu.edu.
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Your participation in this research is voluntary, and you will not be penalized or lose
benefits if you refuse to participate or decide to stop. You may keep a copy of this form for your
records.
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Appendix F
Pretest Survey
Dear Participant:
The purpose of this study is to improve awareness, knowledge, and screening of
genitourinary syndrome of menopause among primary care providers. Your participation is
valued and appreciated.
Please rate the degree to which you agree or disagree with each statement:
Statement
1. I am familiar with the term Genitourinary
Syndrome of Menopause (GSM)
2. I feel that GSM should be routinely addressed
and treated in the primary care setting.
3. I am familiar with the impact of GSM on
afflicted women, the healthcare system, and
society in general.
4. I regularly screen for GSM in my current
practice.
5. I am familiar with the Day-to Day Impact of
Vaginal Aging (DIVA) questionnaire.
6. I am confident in my knowledge of OTC
options for management of GSM.
7. I am confident in my knowledge of
prescription non-hormonal topical treatments
for management of GSM.
8. I am confident in my knowledge of
prescription non-hormonal oral treatments for
GSM.
9. I am confident in my knowledge of
prescription hormonal topical treatments for
GSM.
10. I am familiar with current guidelines on the
safe use of topical hormonal treatments for
GSM.
11. In general, I feel confident in my ability to
effectively address GSM with my patients.

1
Strongly
Disagree

2
3
Disagree Neutral

4
Agree

5
Strongly
Agree
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Appendix G
Posttest Survey
After completion of the genitourinary syndrome of menopause presentation, kindly
complete the post-test survey below.
Please rate the degree to which you agree or disagree with each statement:
Statement
1. I am familiar with the term Genitourinary
Syndrome of Menopause (GSM)
2. I feel that GSM should be routinely addressed
and treated in the primary care setting.

I.
II.
III.

IV.

V.

VI.

VII.

3. I am familiar with the impact of GSM on
afflicted women, the healthcare system, and
society in general.
4. I plan to routinely screen for GSM in my
current practice.
5. I am familiar with the Day-to Day Impact of
Vaginal Aging (DIVA) questionnaire.
6. I am confident in my knowledge of OTC
options for management of GSM.
7. I am confident in my knowledge of
prescription non-hormonal topical treatments
for management of GSM.
8. I am confident in my knowledge of
prescription non-hormonal oral treatments for
GSM.
9. I am confident in my knowledge of
prescription hormonal topical treatments for
GSM.
10. I am familiar with current guidelines on the
safe use of topical hormonal treatments for
GSM.
11. In general, I feel confident in my ability to
effectively address GSM with my patients.

1
Strongly
Disagree

2
3
Disagree Neutral

4
Agree

5
Strongly
Agree
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Appendix H
Day-to-Day Impact of Vaginal Aging (DIVA) Questionnaire
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